Inovio Pharmaceuticals develops vaccines to prevent and treat cancers and challenging infectious diseases. Inovio’s SynCon® vaccines are designed to provide universal cross-strain protection against known diseases, as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines are used in combination with Inovio’s proprietary electroporation delivery to generate best-in-class immune responses with a favorable safety profile. Inovio’s clinical programs include phase II studies for cervical dysplasia, leukemia, and hepatitis C virus and phase I studies for influenza and HIV. For more information visit the company’s Web site at www.inovio.com

ROTH Capital Partners is a relationship-driven investment bank that primarily focuses on connecting small-cap publicly traded companies with institutional investors. This year’s annual ROTH conference will take place at The Ritz Carlton located in Dana Point, CA, on March 11-14. Bringing together executives from more than 400 growth companies, the 24th Annual ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com

Let us hear your thoughts below: